Michael Lassmann
Overview
Explore the profile of Michael Lassmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
2944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salas-Ramirez M, Lassmann M, Eberlein U
EJNMMI Res
. 2025 Mar;
15(1):21.
PMID: 40063302
Background: The aim of this study is to evaluate the induction of DNA damage by 45 radionuclides, including those used in medical applications and others relevant to radiation protection. The...
2.
van Leeuwen F, Pouget J, Lassmann M
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39838151
No abstract available.
3.
Kesner A, Brosch-Lenz J, Gear J, Lassmann M
J Nucl Med
. 2025 Jan;
66(2):166-172.
PMID: 39778969
Dosimetry is integral to informed implementation of radiopharmaceutical therapies, enabling personalized treatment planning and ensuring patient safety by calculating absorbed doses to organs and tumors. As the therapeutic radiopharmaceutical field...
4.
Lassmann M, Eberlein U, Verburg F
Eur J Nucl Med Mol Imaging
. 2025 Jan;
52(4):1246-1248.
PMID: 39743614
No abstract available.
5.
Pouget J, Minguez Gabina P, Herrmann K, Deandreis D, Konijnenberg M, Taieb D, et al.
Eur J Nucl Med Mol Imaging
. 2024 Nov;
52(3):1210-1222.
PMID: 39531084
Purpose: This study by the EANM radiobiology working group aims to analyze the efficacy and toxicity of targeted radionuclide therapy (TRT) using radiopharmaceuticals approved by the EMA and FDA for...
6.
Carter L, Ocampo Ramos J, Schuerrle S, Marquis H, Lassmann M, Bolch W, et al.
J Nucl Med
. 2024 Sep;
65(11):1808-1814.
PMID: 39327016
In nuclear medicine, estimating the number of radioactive decays that occur in a source organ per unit administered activity of a radiopharmaceutical (i.e., the time-integrated activity coefficient [TIAC]) is an...
7.
Strobel I, Schumann S, Muller J, Buck A, Port M, Lassmann M, et al.
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201316
The combination of high and low LET radionuclides has been tested in several patient studies to improve treatment response. Radionuclide mixtures can also be released in nuclear power plant accidents...
8.
Leube J, Claeys W, Gustafsson J, Salas-Ramirez M, Lassmann M, Koole M, et al.
EJNMMI Phys
. 2024 Jun;
11(1):52.
PMID: 38937408
Background: Although the importance of quantitative SPECT has increased tremendously due to newly developed therapeutic radiopharmaceuticals, there are still no accreditation programs to harmonize SPECT imaging. Work is currently underway...
9.
Mazzoni L, Damilakis J, Guen B, Haghdoost S, Rottger A, Siiskonen T, et al.
Phys Med
. 2024 Jun;
124:103392.
PMID: 38862325
The International Commission on Radiological Protection (ICRP), recently expressed concern that "a shortage of investment in training, education, research, and infrastructure seen in many sectors and countries may compromise society's...
10.
Schumann S, Scherthan H, Hartrampf P, Goring L, Buck A, Port M, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791531
This work reports on a model that describes patient-specific absorbed dose-dependent DNA damage response in peripheral blood mononuclear cells of thyroid cancer patients during radioiodine therapy and compares the results...